Aging Overview

External factors

External factors: Aβ1-42 oligomers
Aging type: Accelerate
Aging characteristic:
Category: Chemical compounds
Phenotype: Alzheimer's disease
Experimental category: L
Tissue type: --
Cell name: HBMEC
PMID: 30576228
Experiment: SA-β-gal activity assay// Western blot
Description: HBMECs exposed to Aβ1-42 oligomers appeared flattened and enlarged and showed increased senescence-associated β-galactosidase staining, exhibiting hallmark features of a senescent phenotype.Western blot analysis showed significantly increased p21 protein levels in the Aβ1-42 oligomer-treated HBMECs compared with control group.


Regulatory relationship

Regulatory pathway: VEGFR//p21-p53
R-EF-Pathway: Upregulation//Upregulation
Official symbol(s): KDR//CDKN1A-TP53
Pathway experiment: Western blot//qRT-PCR
Pathway description: Upon Aβ1-42 oligomer treatment, we observed a significant increase in VEGFR-1 protein levels, whereas protein levels of VEGFR-2 were not significantly altered.Western blot analysis showed significantly increased VEGFR-1 protein levels only in the Aβ1-42 oligomer-treated HBMECs but not in either Aβ1-42 monomers or Aβ1-42 fibrils-treated HBMECs .Western blotting analysis from chimeric receptor EGLT-transfected lysates confirmed the increased expression of the VEGFR-1 protein and increased p21 proteins levels and decreased expression of VEGFR-2 levels. qRT-PCR analysis showed increased mRNA levels of VEGFR-1, p21,and p53. There was a decrease in the p53 isoform Δ133p53 mRNA levels and no significant changes in p53b or VEGFR-2 mRNA levels.Western blot analysis showed increased levels of VEGFR-1 and p21 protein expression following Aβ1-42 oligomer treatment compared with control groups as previously shown.


Aging network

Annotation:

The green line represents Upregulation.

The purple line represents Downregulation.

The orange line represents Activation.

The yellow line represents Inhibition.

The gray line represents Unclear.



Pathway view